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OBJECTIVES We studied the value of a rapid beta-blocker injection at peak dobutamine-atropine stress
echocardiography (DASE) for the detection of coronary artery disease (CAD).
BACKGROUND The presence of tachycardia and hyperdynamic wall motion may make it difficult to recognize
a new wall motion abnormality (NWMA) at peak stress.
METHODS We studied 101 patients (mean age 58.2  9.8 years) who underwent effective DASE and
coronary angiography. All patients received a rapid intravenous injection of metoprolol
immediately after peak DASE image acquisition. Positivity in combined peak plus post-
metoprolol images was defined when there was only peak NWMA, maintenance of peak
NWMA, or NWMA detected only after metoprolol injection. Significant CAD was defined
as 50% stenosis by quantitative angiography.
RESULTS There were 37 patients without and 64 with CAD. The sensitivity, specificity, accuracy, and
positive and negative predictive values for the detection of CAD at peak stress were 84%,
92%, 87%, 95%, and 77%, respectively. Five patients with CAD had negative peak images
that became positive only after metoprolol. Extension of peak NWMA during metoprolol
was observed in 14 patients, and multivessel CAD was detected in 10 of them. The
sensitivity, specificity, accuracy, and positive and negative predictive values for peak plus
metoprolol images were 92%, 89%, 91%, 94%, and 87%, respectively.
CONCLUSIONS The use of metoprolol injected at peak of dobutamine infusion improved the detection of
CAD by DASE. (J Am Coll Cardiol 2003;41:1583–9) © 2003 by the American College of
Cardiology Foundation
Dobutamine-atropine stress echocardiography (DASE) is a
safe and established technique for the diagnosis of signifi-
cant coronary artery disease (CAD), and beta-blockers have
been used to reverse its side effects for many years (1–3).
Despite an acceptable accuracy, many factors influence false
results and raise questions about the true sensitivity of
DASE (4). After the clinical observation of a single case, we
hypothesized that one way of overcoming the adverse influ-
ences of tachycardia and hyperkinesia was to examine recovery-
phase images after a rapid intravenous injection of a selective
beta1 receptor antagonist at peak DASE in order to improve
the detection of a new wall motion abnormality (NWMA).
METHODS
Patients. Between February 2000 and January 2002,
DASE was performed in 1,265 patients with known or
suspected CAD. Of these, 101 consecutive patients who
had an effective DASE study, with beta-blocker injection at
peak stress as well as a clinically indicated coronary angio-
gram within three months, were included in this study. The
following exclusion criteria were observed: previous coro-
nary artery bypass graft surgery, acute myocardial infarction,
unstable angina, hypertension at rest or during stress (180
and/or 110 mm Hg), an intervening event between DASE
and quantitative coronary angiography (QCA), or contra-
indications to any drug used in the study. No patient was
excluded on the basis of the results of rest echocardiography.
The study was approved by our institutional Ethical Com-
mittee, and written, informed consent was obtained from all
participants.
Protocol. Dobutamine was administered in a standard
fashion, and atropine was injected at the beginning of the
stage of 20 g/kg per min if the heart rate (HR) was 100
beats/min. Immediately after acquisition of peak stress
(peak) images, 5 mg metoprolol was injected in 1 min on
termination of dobutamine infusion (Fig. 1).
Echocardiographic measurements. Examinations were
performed using an HDI 5000 or Sonos 5500 from Philips
Medical Systems, Bothell, Washington. Images were ac-
quired at rest, low dose, and peak stress and after metopro-
lol, when HR was below 100 beats/min, or at most 3 min
after the end of the metoprolol injection. The left ventricle
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was divided and measured according to the recommenda-
tions published elsewhere (5).
Peak images were considered positive when there was
inducement of or worsening of a pre-existent wall motion
abnormality. Combined peak plus metoprolol images were
defined as positive when there were only peak images
positivity, maintenance of NWMA observed at peak, ex-
tension of peak NWMA, or detection of NWMA only after
metoprolol.
Intra- and inter-observer agreements were calculated for
a set of 20 stress echocardiograms in a blinded fashion by
two independent observers.
Coronary angiography. QCA was performed with a
computer-assisted analysis system, using standard method-
ology (6), and the images were examined by an experienced
angiographer blinded to clinical and echocardiographic
data. Significant CAD was defined as 50% luminal
diameter stenosis in one or more major coronary arteries.
Multivessel CAD was defined by the presence of significant
left main or two- or three-vessel stenosis.
Statistical analysis. Continuous data are expressed as the
mean 1 SD, and frequency as proportions. Comparisons
between groups for continuous variables were made using
the Student t or Mann-Whitney test, when normality was
rejected. The chi-square and Fisher exact tests were used for
categorical variables. Repetitive measures of variance anal-
ysis were performed for comparisons between groups.
Sensitivity, specificity, predictive values, and accuracy
were calculated according to standard definitions, and 95%
confidence intervals (CIs) were given. The MacNemar test
was used for comparisons between DASE and angiographic
results.
Multivariate stepwise logistic regression analysis was used
to evaluate which variable best-predicted NWMA on meto-
prolol images. Inter-observer agreement was calculated by
the kappa statistic, and intra-observer agreement by Spear-
man correlation. A two-tailed p value0.05 was considered
statistically significant.
RESULTS
The study population was constituted by 101 patients (58.2
 9.8 years old; 61 men). Hypertension was documented in
75 patients, diabetes mellitus in 24 patients, dyslipidemia in
61 patients, cigarette smoking in 27 patients, previous
myocardial infarction in 16 patients, and a history of chest
pain in 60 patients. Regarding medical therapy, 46 patients
were treated with nitrates, 36 with calcium antagonists, 72
with aspirin, and 46 with beta-blockers. Thirty-seven pa-
tients had no CAD, and 64 patients had CAD, with
multivessel disease detected in 38 (59%) of them.
The dosage of dobutamine used was 30.8  7.6 g/kg
per min. Atropine (0.7  0.5 mg) was used in 91 patients
(90%). No major test-related complication was observed.
Detection of CAD by DASE. At peak images, there were
10 false-negative and 3 false-positive results. Analysis of
peak images alone presented sensitivity, specificity, and
positive and negative predictive values of 84% (95% CI 74%
Abbreviations and Acronyms
CAD  coronary artery disease
CI  confidence interval
DASE  dobutamine-atropine stress echocardiography
HR  heart rate
NWMA  new wall motion abnormality
QCA  quantitative coronary angiography
WMSI  wall motion score index
Figure 1. Dobutamine-atropine stress echocardiography—metoprolol protocol. EKG  electrocardiogram.
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to 91%), 92% (95% CI 78% to 97%), 95% (95% CI 85% to
98%), and 77% (95% CI 63% to 87%), respectively, with an
overall accuracy of 87% for detection of CAD.
There were five patients with CAD not detected on peak
images in whom NWMAs were observed only after meto-
prolol injection. Yet, there were increases of sensitivity to
92% (95% CI 83% to 97%), negative predictive value to 87%
(95% CI 73% to 94%), and overall accuracy to 91%, with
maintenance of specificity and positive predictive values of
89% (95% CI 75% to 96%) and 94% (95% CI 85% to 97%),
respectively (Fig. 2). There was only a new patient with
normal peak images and marked lateral wall hypokinesia,
associated with ST-segment elevation observed only after
metoprolol injection (false-positive), who had a 40% diag-
onal branch lesion.
Patients with single-vessel disease showed an increase in
sensitivity from 73% (95% CI 54% to 86%) to 88% (95% CI
66% to 94%). On the other hand, in patients with multives-
sel disease, the sensitivity at peak stress was 92% (95% CI
79% to 97%), and at peak stress plus metoprolol, it was 95%
(95% CI 86% to 98%), with no difference between their
values (Fig. 3).
Patterns of response to metoprolol. Negative results of
metoprolol injection were obtained in 17 patients (27%). In
12 of them, NWMA was detected at peak DASE with
complete recovery after metoprolol, and in five it was
negative in both sets of images. On the other hand, 47
patients (73% of all patients with CAD) had positive results
with metoprolol (maintenance of NWMA detected at peak
stress in 28 patients, extension in 14 patients, and NWMA
Figure 2. Sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) for the detection of CAD for peak (open
bars) and peak plus metoprolol images (solid bars).
Figure 3. Sensitivity values in patients with single-vessel (solid bars) and multivessel coronary artery disease (open bars) at peak and peak plus metoprolol
(Met) images.
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detected only after beta-blocker injection in 5 patients). Of
these five patients, four had single-vessel stenosis with
coronary obstructions between 50% and 69% in three, and
only one had multivessel disease (Figs. 4 and 5). Table 1
summarizes their hemodynamics.
On multivariate regression analysis, the presence of mul-
tivessel disease was found to be the only independent
predictor of extension of NWMA (10 of 14 patients) after
metoprolol injection (odds ratio [OR] 7.8, 95% CI 2.0 to
30.8; p  0.0032). No other variable correlated with
recovery or maintenance of NWMA (Table 2).
Echocardiographic indexes at rest and during DASE are
demonstrated in Table 3.
Intra-observer and inter-observer agreement. We ob-
served excellent correlation between the two measurements
for the same observer (intra-observer agreement) for rest (r
 0.97, p  0.001), low-dose (r  0.98, p  0.001), peak
(r  0.96, p  0.001), and metoprolol images (r  0.93, p
 0.001). The global inter-observer agreement was 93%
(kappa  0.75, p  0.001).
DISCUSSION
Routinely, most echocardiographic laboratories utilize beta-
blockers when a significant and hemodynamically important
myocardial ischemic event is elicited during DASE (2,3).
The overall accuracy of peak DASE reported in this study
resembles that of the current literature for the presence of
significant CAD (1). Our results may seem unexpected
since a decrease, and not an increase, of sensitivity due to the
protective effect of beta-blockade in relieving myocardial
ischemia, triggered by a pharmacologic stress test, would be
the obvious finding. It has been shown by echocardiography
in patients with unstable angina (7) or during balloon
angioplasty (8) that beta-blockade ameliorates the electro-
cardiographic and echocardiographic signs of myocardial
ischemia. Also, the use of a beta-blocker is an established
therapy in patients with CAD, due to its protective effects
on myocardial oxygen consumption, thereby preventing
ischemic events. This protective effect is mainly due to a
decrease in the rate–pressure product (7–9).
Paradoxically, we demonstrated that the combined peak
Figure 4. Example of a patient with 90% left anterior descending coronary artery stenosis without new wall motion abnormality at peak stress developed
only after metoprolol. Apical four-chamber views at end systole with normal thickening at rest (heart rate of 46 beats/min; rate–pressure product of 6,578
mm Hg/min; and left ventricular end-systolic volume index [LVESVI] of 15.7 ml/m2) and low doses. At peak stress, HR was 139 beats/min, rate–pressure
product was 20,850 mm Hg/min, and LVESVI was 12.8 ml/m2. After metoprolol, there is a lack of thickening in the apical septum (white arrows; HR
of 103 beats/min; rate–pressure product of 15,450 mm Hg/min; and LVESVI of 33.3 ml/m2). For the accompanying video corresponding to Figure 4,
please see the following link:
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plus metoprolol images raised the sensitivity, especially in
patients with single-vessel CAD, without significant a loss
in specificity. To our knowledge, this is the first publication
demonstrating the additional diagnostic increment in sen-
sitivity by applying a bolus injection of a beta-adrenergic
blocker with the purpose of enabling the observation of
NWMA during the early recovery phase.
When injected in the proposed fashion, we demonstrated
that there is a decrease in the rate–pressure product, as
compared with peak stress, but, importantly, this index was
higher at the moment when metoprolol images were ac-
quired than it was at rest. It suggests a sustained oxygen
consumption state, prolonging the ischemic effects of do-
butamine on the myocardium through the recovery phase.
Furthermore, as most of stress-induced ischemia is limited
to the subendocardium, ischemia may be masked by the
hyperdynamic contractile state from the mid and epicardial
layers (10–12). Yet, we observed an elevated rate–pressure
Figure 5. An electrocardiogram from the patient in Figure 4, demonstrating ST-segment changes in leads D2, D3, aVF, V5, and V6 only during metoprolol
(Met).
Table 1. Hemodynamic Parameters
Variables
Non-CAD
Patients
(n  37)
CAD Patients With
Negative Results
With Metoprolol
(n  17)
CAD Patients With
Positive Results
With Metoprolol
(n  47) p Value‡
Baseline
HR (beats/min) 72  11 71  9 72  10 NS
SBP (mm Hg) 139  11 145  16 142  13 NS
DBP (mm Hg) 87  8 88  9 87  9 NS
RPP (mm Hg/min) 10  2  103 11  1  103 10  2  103 NS
Peak stress
HR (beats/min) 149  18 136  18 137  21 0.014
SBP (mm Hg) 159  30 157  30 155  30 NS
DBP (mm Hg) 86  16 82  21 85  19 NS
RPP (mm Hg/min) 24  5  103 21  5  103 21  4  103 NS
Post-metoprolol
HR (beats/min) 95  13* 101  8* 96  16* NS
SBP (mm Hg) 137  23† 149  27† 144  27† NS
DBP (mm Hg) 81  13* 90  17† 85  16† NS
RPP (mm Hg/min) 13  3  103* 14  5  103* 14  4  103* NS
*p 0.05 compared with baseline. †p NS compared with baseline. ‡Between CAD patients with positive and negative results
with metoprolol. Data are expressed as the mean value  SD.
CAD  coronary artery disease; DBP  diastolic blood pressure; HR  heart rate: NS  not significant; RPP 
rate–pressure product; SBP  systolic blood pressure.
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Table 2. Distribution of Coronary Artery Disease in Patients With Negative and Positive Results With Metoprolol
CAD Group With Negative Results With Metoprolol (n  17)
SVD (n  7)/41% MVD (n  10)/59%
LAD RCA LCx Two-vessel Three-vessel
5 (2/3) 1 (1/–) 1 (–/1) 7 (1/6) 3 (–/3)
CAD Group With Positive Results With Metoprolol (n  47)
Maintenance of Peak NWMA (n  28)
SVD (n  11)/39% MVD (n  17)/61%
LAD RCA LCx Two-vessel Three-vessel
6 (3/3) 4 (1/3) 1 (1/–) 11 (–/11) 6 (–/6)
Extension of Peak NWMA (n  14)
SVD (n  4)/28% MVD (n  10)/71%
LAD RCA LCx Two-vessel Three-vessel
3 (–/3) — 1 (–/1) 5 (–/5) 5 (–/5)
NWMA Only After Metoprolol (n  5)
SVD (n  4)/80% MVD (n  1)/20%
LAD RCA LCx Two-vessel Three-vessel
4 (3/1) — — — 1 (1/–)
Data are expressed as the number (%) of patients. Values in parentheses express patients with stenosis between 50% and 69%/patients with at least one coronary stenosis 70%.
LAD  left anterior descending territory; LCx  left circumflex territory; MVD  multivessel disease; RCA  right coronary artery territory; SVD  single-vessel disease.
Table 3. Echocardiographic Variables at Baseline and During Dobutamine-Atropine Stress Echocardiography
Variables
Non-CAD Group
(n  37)
CAD Patients With Negative
Results With Metoprolol
(n  17)
CAD Patients With Positive
Results With Metoprolol
(n  47)
p Value Between CAD
Patients With Positive and
Negative Results With
Metoprolol
LVMI (g/m2) 107  25* 129  37 127  39 NS
RWT 0.40  0.06† 0.37  0.08 0.39  0.06 NS
LVEDVI (ml/m2)
Baseline 51  14* 90  36 73  38 NS
Low doses 50  12* 80  32 71  44 NS
Peak 40  14* 71  36 60  37 NS
Metoprolol 47  11*‡ 73  32‡ 66  35‡ NS
LVESVI (ml/m2)
Baseline 17  6* 51  35 37  32 NS
Low doses 11  5* 39  31 31  32 NS
Peak 7  3* 39  35 28  31 NS
Metoprolol 14  5*‡ 43  31§ 36  29§ NS
LVEF (%)
Baseline 67  7* 51  16 57  15 NS
Low doses 78  7* 60  21 67  17 NS
Peak 82  6* 56  23 60  19 NS
Metoprolol 69  9§ 50  18§ 52  16‡ NS
WMSI
Baseline 1.00  0.02* 1.42  0.66 1.32  0.46 NS
Low doses 1.0* 1.33  0.57 1.23  0.39 NS
Peak 1.01  0.05* 1.57  0.66 1.60  0.48 NS
Metoprolol 1.04  0.15*§ 1.42  0.66§ 1.65  0.48‡ 0.006
*p  0.05 compared with CAD group with negative and positive results. †p  NS compared with CAD group with negative and positive results. ‡p  0.05 between metoprolol
and baseline. §p  NS between metoprolol and baseline. Data are expressed as the mean value  SD.
CAD  coronary artery disease; LVEDVI  left ventricular end-diastolic volume index; LVEF  left ventricular ejection fraction; LVESVI  left ventricular end-systolic
volume index; LVMI  left ventricular mass index; RWT  relative wall thickness; WMSI  wall motion score index.
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product associated with an increase in the left ventricular
end-systolic volume index at metoprolol when compared to
values at rest. Perhaps this allowed the detection and,
sometimes, exacerbation of NWMA that simply was diffi-
cult to see at peak stress. Thus, the advantage of using this
strategy may be related solely to the enhanced ability to
visualize the NWMA.
Another reasonable associated mechanism would be the
abrupt reduction of coronary vasodilation through simulta-
neous blockade of beta1 and beta2 receptors, by rapid
injection of metoprolol, resulting in an abrupt, unopposed
alpha receptor–mediated reduction in coronary flow reserve
(9,13). A rare and extreme side of this theory would be the
occurrence of coronary vasospasm induced by the acute
blockage of beta receptors, during high doses of dobut-
amine, associated with alpha receptor liberation mediated by
metoprolol (2). Actually, this could explain the false-
positive case we had in a patient that presented with marked
lateral wall hypokinesia and electrocardiographic changes
only after metoprolol. Therefore, in this setting, myocardial
ischemia would result from increased coronary artery vaso-
constriction, leading to an increase in coronary resistance
and a decrease in coronary artery blood flow (13).
Study limitations. The relatively small number of patients
with CAD did not allow a detailed statistical analysis of the
relationship between the two groups of different responses
to metoprolol and many other important variables. Also,
because the study was performed in patients referred to
coronary angiography, we recognize that there is a selection
bias, but since the patient’s images were compared to
themselves, this issue is minimized.
Although an intravenous injection of a standard dose of 5
mg metoprolol does not work similarly for every patient, it
has been used for more than a decade in the same fashion
and was chosen because we did not want to propose changes
in the routine (1–3).
The observation of two specific types of response to
metoprolol in patients with CAD suggests that there might
be other mechanical, vascular, or metabolic mechanisms
involved in this process that we were unable to account for.
This study was designed to document, for the first time,
the value of a clinically observed phenomenon; therefore, we
recognize that most proposed mechanisms are unknown at
this time, warranting further studies.
Clinical implications. The most important contribution of
this work would be with respect to those patients who
achieved 85% of the target HR and still have a negative
DASE. In those cases, rapid administration of a beta-
blocker at peak DASE will promote an increase in the
detection of CAD, especially in patients with single-vessel
CAD, a recognized limitation of DASE (4).
This strategy can also be useful in patients whose peak
DASE images are doubtful for ischemia, therefore ratifying
the NWMA observed at peak stress. On the other hand, in
patients with clearly positive peak images, the time to
recovery of the induced NWMA is an important predictor
of the severity of CAD; therefore, the proposed strategy
could compromise this important prognostic information
(14).
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